Alnylam Presentation at JPMorgan 2023.pdf

1、1 2023 Alnylam Pharmaceuticals,Inc.January 9,2023Yvonne Greenstreet,MBChB,MBAChief Executive Officer41stAnnual J.P.Morgan Healthcare ConferenceNathan(USA)Diagnosed with AHP2Alnylam Forward Looking StatementsThis presentation contains forward-looking statements within the meaning of Section 27A of th

2、e Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.Allstatements other than historical statements of fact regarding Alnylams expectations,beliefs,goals,plans or prospects including,without limitation,expectations regarding Alnylamsaspiration to become a leading biotech c

3、ompany and the planned achievement of its“Alnylam P5x25”strategy,the potential for Alnylam to identify new potential drug developmentcandidates and advance its research and development programs,Alnylams ability to obtain approval for new commercial products or additional indications for its existing

4、 products,and Alnylams projected commercial and financial performance should be considered forward-looking statements.Actual results and future plans may differ materially from thoseindicated by these forward-looking statements as a result of various important risks,uncertainties and other factors,i

5、ncluding,without limitation:the direct or indirect impact of theCOVID-19 global pandemic or any future pandemic on our business,results of operations and financial condition and the effectiveness or timeliness of our efforts to mitigate the impactof the pandemic;the potential impact of the January 2

6、022 leadership transition on our ability to attract and retain talent and to successfully execute on our“Alnylam P5x25”strategy;the finalization and audit of our fourth quarter and 2022 fiscal year financial results,which could potentially result in changes or adjustments to the selected preliminary